United Therapeutics Q3 revenue $516M (+16% YoY); net income $239M (+47%)

UNITED THERAPEUTICS Corp

2022-Q3 EPS reported $12.35 revenue$1,444,800,000

Net income per diluted share $4.91; Tyvaso revenues $257.7M (+57% YoY) driven by Tyvaso DPI launch.
Tyvaso achieved $1B annual run-rate; management targets 6,000 patients on Tyvaso by year-end.
R&D expense $66.1M (-17% YoY) due to fair value adjustments; PERFECT study discontinued per DSMC.
TETON 2 study of Tyvaso in IPF enrolled first patient October 2022; TETON 1 enrollment ongoing.
Remunity Pump launched patient-filled version in September 2022 for monthly cassette shipments.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

UNITED THERAPEUTICS Corp reported the quarter ended September 30, 2022 results: revenue $516.0 million, net income $239.3, EPS $4.91.

Period: the quarter ended September 30, 2022
Revenue: $516.0 million
Net income: $239.3
EPS: $4.91
Result: reported results

Exact text from the filing

benefit corporation, today announced its financial results for the quarter ended September 30, 2022. Total revenues in the third quarter of 2022 grew 16% year-over-year to $516.0 million, compared to $444.7 million in the third quarter of 2021. “We are thrilled to report the highest quarterly revenue in our history,” said Martine Rothblatt, Ph.D. , Chairperson

View on SEC.gov

Browse all earnings releases →

UNITED THERAPEUTICS Corp filing history →

Source: SEC EDGAR

accession 0001082554-22-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.